On Tuesday, Abbott Laboratories (NYSE:ABT) stock received a positive outlook from Oppenheimer, as the firm initiated coverage with an Outperform rating and a price target of $130.00. The new price target is based on a projected sales multiple for the fiscal year 2026 and reflects confidence in the company's future performance.
Abbott Labs, known for its diversified healthcare portfolio, is recognized for its MedTech segment, which currently contributes approximately 45% to the company's global sales, estimated at around $42 billion.
This segment is experiencing a growth rate of 11-13% CAGR. In contrast, the non-MedTech division faces slower growth due to ongoing litigation concerning its Pediatric Nutrition Business and diminishing COVID-19 Diagnostics sales.
Despite these challenges, the outlook for Abbott Labs remains positive. As the headwinds affecting the non-MedTech operations begin to wane, the company is expected to see easier comparative financial metrics by the fiscal year 2026. The anticipated top-line growth rate should increase to a low double-digit percentage, coupled with improvements in EBIT margins.
Oppenheimer's coverage initiation highlights the potential for Abbott Labs to overcome current obstacles and achieve stronger financial health in the coming years.
The firm's analysis suggests that as the company navigates through the existing legal and market challenges, its overall growth trajectory will become more robust, supporting the Outperform rating and the $130.00 price target.
In other recent news, Abbott Laboratories has reported strong second-quarter earnings and revenue, primarily driven by the Medical Devices segment. The company's earnings per share of $1.14 surpassed expectations, and revenues reached $10.38 billion.
As a result, Abbott revised its full-year revenue guidance to an organic growth range of 9.5%-10% and raised its EPS guidance to $4.61-$4.71 from the previous $4.55-$4.70 range.
In addition, Abbott has launched its over-the-counter continuous glucose monitoring system, Lingo, in the U.S., and expanded its Pure Bliss by Similac line to include new organic infant formulas. Furthermore, Abbott has entered a global partnership with Medtronic (NYSE:MDT) to develop a continuous glucose monitoring system.
On the analyst front, Piper Sandler initiated coverage on Abbott Laboratories with an Overweight rating, while TD Cowen maintains its Buy rating on Abbott.
Other analyst firms, including Jefferies and BTIG, also maintained positive outlooks on Abbott, citing the strength of the company's diversified portfolio.
However, Abbott is currently facing legal challenges, with nearly 1,000 lawsuits filed against the company and British firm Reckitt Benckiser (LON:RKT), alleging failure to adequately warn healthcare providers of increased disease risks when using their infant formula.
Despite these legal challenges, Abbott continues its long history of consistent shareholder payouts, declaring its 403rd consecutive quarterly dividend of 55 cents per share. These are recent developments for Abbott Laboratories.
InvestingPro Insights
Adding to Oppenheimer's positive outlook on Abbott Laboratories (NYSE:ABT), recent data from InvestingPro provides further context to the company's financial position and market performance. Abbott's market capitalization stands at $197.23 billion, reflecting its significant presence in the healthcare sector. The company's revenue for the last twelve months as of Q2 2024 was $40.73 billion, with a modest growth of 1.24%, aligning with the article's mention of the company's estimated $42 billion in global sales.
InvestingPro Tips highlight Abbott's strong dividend history, having raised its dividend for 11 consecutive years and maintained payments for 54 years. This demonstrates the company's financial stability and commitment to shareholder returns, which could be attractive to investors looking for steady income alongside potential growth.
The company's P/E ratio of 35.6 suggests that investors are willing to pay a premium for Abbott's shares, possibly due to its strong market position and growth prospects in the MedTech segment, as mentioned in the article. This valuation metric, combined with Abbott trading near its 52-week high, indicates market confidence in the company's future performance.
For readers interested in a deeper analysis, InvestingPro offers 11 additional tips on Abbott Laboratories, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.